XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
Total
Preferred Stock
Preferred Stock
Series D Convertible Preferred Stock
Preferred Stock
Series C Convertible Preferred Stock
Common Stock
Common Stock
Series D Convertible Preferred Stock
Common Stock
Series C Convertible Preferred Stock
Additional Paid-In Capital
Additional Paid-In Capital
Series D Convertible Preferred Stock
Additional Paid-In Capital
Series E Convertible Preferred Stock
Additional Paid-In Capital
Series C Convertible Preferred Stock
Service Receivable
Accumulated Deficit
Accumulated Deficit
Series D Convertible Preferred Stock
Accumulated Deficit
Series E Convertible Preferred Stock
Balance, beginning (in shares) at Dec. 31, 2018   60,600     3,831,879                    
Balance, beginning at Dec. 31, 2018 $ 10,084,192 $ 60     $ 7,742     $ 202,267,605       $ 0 $ (192,191,215)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation 200,067             200,067              
Issuance of common stock upon exercise of warrants (in shares)         497,313                    
Issuance of common stock upon exercise of warrants 3,282,266       $ 50     3,282,216              
Issuance of common stock upon vesting of restricted stock units (in shares)         6,362                    
Issuance of common stock upon vesting of restricted stock units         $ 4     (4)              
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)                       (6,060)    
Release of clinical trial funding commitment 70,487                     70,487      
Net loss (3,904,771)                       (3,904,771)    
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)   200,000     183,334                    
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (40,000) $ 200     $ 110     1,634,690       (1,675,000)      
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance               268,269         (268,269)    
Issuance of common stock for share rounding as a result of reverse stock split (in shares)         6,466                    
Balance, ending (in shares) at Mar. 31, 2019   260,600     4,525,354                    
Balance, ending at Mar. 31, 2019 9,686,181 $ 260     $ 7,906     207,652,843       (1,604,513) (196,370,315)    
Balance, beginning (in shares) at Dec. 31, 2018   60,600     3,831,879                    
Balance, beginning at Dec. 31, 2018 10,084,192 $ 60     $ 7,742     202,267,605       0 (192,191,215)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Net loss (12,171,623)                            
Balance, ending (in shares) at Sep. 30, 2019   60,600     6,436,505                    
Balance, ending at Sep. 30, 2019 6,655,980 $ 60     $ 8,096     212,463,077       (1,165,966) (204,649,287)    
Balance, beginning (in shares) at Mar. 31, 2019   260,600     4,525,354                    
Balance, beginning at Mar. 31, 2019 9,686,181 $ 260     $ 7,906     207,652,843       (1,604,513) (196,370,315)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation 148,834             148,834              
Sale of common stock and warrants (in shares)         (421,917)                    
Sale of common stock and warrants (2,902,740)       $ (42)     (2,902,698)              
Issuance of common stock upon exercise of warrants (in shares)         156,353                    
Issuance of common stock upon exercise of warrants 1,564       $ 16     1,548              
Issuance of common stock upon vesting of restricted stock units (in shares)         4,433                    
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)                       (6,060)    
Release of clinical trial funding commitment 240,279                     240,279      
Net loss (4,125,303)                       (4,125,303)    
Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)       (200,000)     333,333                
Issuance of common stock upon conversion of Series D Convertible Preferred Stock       $ (200)     $ 33       $ 167        
Balance, ending (in shares) at Jun. 30, 2019   60,600     5,441,390                    
Balance, ending at Jun. 30, 2019 8,848,235 $ 60     $ 7,997     210,706,090       (1,364,234) (200,501,678)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation 266,325             266,325              
Sale of common stock and warrants (in shares)         (271,744)                    
Sale of common stock and warrants (1,483,581)       $ (27)     (1,483,554)              
Issuance of common stock upon exercise of warrants (in shares)         717,969                    
Issuance of common stock upon exercise of warrants 7,180       $ 72     7,108              
Issuance of common stock upon vesting of restricted stock units (in shares)         5,402                    
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)                       (6,060)    
Release of clinical trial funding commitment 198,268                     198,268      
Net loss (4,141,549)                       (4,141,549)    
Balance, ending (in shares) at Sep. 30, 2019   60,600     6,436,505                    
Balance, ending at Sep. 30, 2019 6,655,980 $ 60     $ 8,096     212,463,077       (1,165,966) (204,649,287)    
Balance, beginning (in shares) at Dec. 31, 2019   60,600     8,593,633                    
Balance, beginning at Dec. 31, 2019 7,311,344 $ 60     $ 8,312     217,172,528       (971,673) (208,897,883)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation 177,309             177,309              
Sale of common stock and warrants (in shares)         (800,000)                    
Sale of common stock and warrants (1,000,001)       $ (80)     (999,921)              
Issuance of common stock upon exercise of warrants (in shares)         1,610,144                    
Issuance of common stock upon exercise of warrants 1,456,369       $ 161     1,456,208              
Issuance of common stock upon vesting of restricted stock units (in shares)         6,810                    
Issuance of common stock upon vesting of restricted stock units         $ 1     (1)              
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)                       (6,060)    
Release of clinical trial funding commitment 293,017                     293,017      
Net loss (4,088,562)                       (4,088,562)    
Balance, ending (in shares) at Mar. 31, 2020   60,600     11,010,587                    
Balance, ending at Mar. 31, 2020 6,143,418 $ 60     $ 8,554     219,805,965       (678,656) (212,992,505)    
Balance, beginning (in shares) at Dec. 31, 2019   60,600     8,593,633                    
Balance, beginning at Dec. 31, 2019 7,311,344 $ 60     $ 8,312     217,172,528       (971,673) (208,897,883)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Net loss (12,709,625)                            
Balance, ending (in shares) at Sep. 30, 2020   926,424     26,285,743                    
Balance, ending at Sep. 30, 2020 33,522,550 $ 926     $ 10,081     260,807,295       (2,403,580) (224,892,172)    
Balance, beginning (in shares) at Mar. 31, 2020   60,600     11,010,587                    
Balance, beginning at Mar. 31, 2020 6,143,418 $ 60     $ 8,554     219,805,965       (678,656) (212,992,505)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation 281,776             281,776              
Issuance of common stock upon exercise of warrants (in shares)         3,473,393                    
Issuance of common stock upon exercise of warrants 4,605,017       $ 347     4,604,670              
Issuance of common stock upon vesting of restricted stock units (in shares)         2,250                    
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)                       (6,060)    
Release of clinical trial funding commitment 213,492                     213,492      
Net loss (4,124,532)                       (4,124,532)    
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)   154,670     602,833                    
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (7,500) $ 15     $ 60     2,292,425       (2,300,000)      
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance                 $ 601,767 $ 2,664,717       $ (601,767) $ (2,664,717)
Sale of common stock, preferred stock and warrants (in shares) [1]   865,824     4,689,313                    
Sale of common stock, preferred stock and warrants [1] (17,278,428) $ 866     $ 469     17,277,093              
Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)     (154,670)     1,546,700                  
Issuance of common stock upon conversion of Series D Convertible Preferred Stock     $ (15)     $ 155     $ (140)            
Balance, ending (in shares) at Jun. 30, 2020   926,424     21,325,076                    
Balance, ending at Jun. 30, 2020 24,384,039 $ 926     $ 9,585     247,528,273       (2,765,164) (220,389,581)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation 361,884             361,884              
Issuance of common stock upon exercise of warrants (in shares)         4,956,084                    
Issuance of common stock upon exercise of warrants 12,910,802       $ 496     12,910,306              
Issuance of common stock upon vesting of restricted stock units (in shares)         1,250                    
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)                       (6,060)    
Release of clinical trial funding commitment 361,584                     361,584      
Net loss (4,496,531)                       (4,496,531)    
Issuance of common stock upon exercise of stock options (in shares)         3,333                    
Issuance of common stock upon exercise of stock options 6,832             6,832              
Balance, ending (in shares) at Sep. 30, 2020   926,424     26,285,743                    
Balance, ending at Sep. 30, 2020 $ 33,522,550 $ 926     $ 10,081     $ 260,807,295       $ (2,403,580) $ (224,892,172)    
[1] Net of expenses of $616,143, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666.